Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals"

Breast Cancer Research and Treatment

Volumn 96, Issue 3, 2006, Pages 233-241

  Manjili, Masoud H ^a   Arnouk, Hilal ^b   Knutson, Keith L ^c   Kmieciak, Maciej ^a   Disis, Mary L ^d   Subjeck, John R ^b   Kazim, A Latif ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Danger signal; Heat shock proteins; HER 2 neu; Tumor escape

Indexed keywords

BETA ACTIN; CALRETICULIN; CHAPERONE; CORTACTIN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIGEN; GLYCOPROTEIN GP 96; PROTEIN P57; RANTES; RHO FACTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER PREVENTION; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CELL ISOLATION; CELL LINE; CELL MOTILITY; COMPARATIVE STUDY; CONGENIC ANIMAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INFLAMMATION; INOCULATION; LATENT PERIOD; METABOLISM; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR REJECTION; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CHEMOKINES, CC; CORTACTIN; CYTOKINES; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM PROTEINS; PROTEOMICS; RECEPTOR, ERBB-2; TUMOR ESCAPE;

EID: 33645721261     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9044-4     Document Type: Article

References (34)

1. Skoberne M, Beignon AS, Bhardwaj N: Danger signals: a time and space continuum. Trends Mol Med 10: 251-257, 2004
2. Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y: Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 53: 543-550, 2004
3. Lavergne E, Combadiere C, Iga M, Boissonnas A , Bonduelle O , Maho M , Debre P , Combadiere B: Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 173: 3755-3762, 2004
4. Weber C, Weber KS, Klier C, Gu S, Wank R, Horuk R, Nelson PJ: Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood 97: 1144-1146, 2001
5. Oppenheim JJ, Yang D, Biragyn A, Howard OM, Plotz P: Chemokine receptors on dendritic cells promote autoimmune reactions. Arthritis Res 4(Suppl 3): S183-188, 2002
6. Yang Y, Ochando J, Yopp A, Bromberg JS, Ding Y: IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation. J Immunol 174: 2720-2729, 2005
7. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S: Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 161: 4652-4660, 1998
8. Radsak MP, Hilf N, Singh-Jasuja H, Braedel S, Brossart P, Rammensee HG, Schild H: The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood 101: 2810-2815, 2003
9. Baker-LePain JC, Sarzotti M, Nicchitta CV: Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo. J Immunol 172: 4195-4203, 2004
10. Baker-LePain JC, Sarzotti M, Fields TA, Li CY, Nicchitta CV: GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J Exp Med 196: 1447-1459, 2002
11. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521, 2003
12. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA: HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5: 825-830, 2004
13. Demarco RA, Fink MP, Lotze MT: Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol 42: 433-444, 2005
14. Shacter E, Weitzman SA: Chronic Inflammation and Cancer. Oncology 16: 217-232, 2002
15. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998, 2003
16. Muller WJ, Arteaga CL, Muthuswamy SK, Siegel PM, Webster MA, Cardiff RD, Meise KS, Li F, Halter SA, Coffey RJ: Synergistic interaction of the neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 16: 5726-5736, 1996
17. Knutson KL, Almand B, Dang Y, Disis ML: Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 64: 1146-1151, 2004
18. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, Currie I: A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3: 36-44, 2003
19. Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, Timms JF: Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics 1: 91-98, 2002
20. Lee CL, Hsiao HH, Lin CW, Wu SP, Huang SY, Wu CY, Wang AH, Khoo KH: Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines. Proteomics 3: 2472-2486, 2003
21. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148, 2004
22. Hoffmann TK, Meidenbauer N, Muller-Berghaus J, Storkus WJ, Whiteside TL: Proinflammatory Cytokines and CD40 Ligand Enhance Cross-Presentation and Cross-Priming Capability of Human Dendritic Cells Internalizing Apoptotic Cancer Cells. J Immunother 24: 162-171, 2001
23. Zimmermann VS, Bondanza A, Monno A, Rovere-Querini P, Corti A, Manfredi AA: TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens. J Immunol 172: 2643-2650, 2004
24. Pasare C, Medzhitov R: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036, 2003
25. Rochman I, Paul WE, Ben-Sasson SZ: IL-6 increases primed cell expansion and survival. J Immunol 174: 4761-4767, 2005
26. Robert J, Gantress J, Rau L, Bell A, Cohen N: Minor histocompatibility antigen-specific MHC-restricted CD8 T cell responses elicited by heat shock proteins. J Immunol 168: 1697-703, 2002
27. Berwin B, Delneste Y, Lovingood RV, Post SR, Pizzo SV: SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J Biol Chem 279: 51250-51257, 2004
28. Reed RC, Berwin B, Baker JP, Nicchitta CV: GRP94/gp96 elicits ERK activation in murine macrophages. A role for endotoxin contamination in NF-kappa B activation and nitric oxide production. J Biol Chem 278: 31853-31860, 2003
29. Fonteneau JF, Larsson M, Bhardwaj N: Dendritic cell-dead cell interactions: implications and relevance for immunotherapy. J Immunother 24: 294-304, 2001
30. Lin M, van Golen KL: Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat 84: 49-60, 2004
31. Knutson KL, Almand B, Dang Y, Disis ML: Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 64: 1146-1151, 2004
32. Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, Simon R, Liu ET, Green JE: Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A 99: 6967-6972, 2002
33. Li Y, Tondravi M, Liu J, Smith E, Haudenschild CC, Kaczmarek M, Zhan X: Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 61: 6906-6911, 2001
34. Kaufman HL, Disis ML: Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest 113: 664-667, 2004